Molecular diagnostics firm CareDx Inc. netted $18.8mm through the follow-on public offering of 4.99mm common shares (including full exercise of the overallotment) at $4 each. (Oct.)
Investment Banks/Advisors: Craig-Hallum Inc.; HC Wainwright & Co.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.
Molecular diagnostics firm CareDx Inc. netted $18.8mm through the follow-on public offering of 4.99mm common shares (including full exercise of the overallotment) at $4 each. (Oct.)
Investment Banks/Advisors: Craig-Hallum Inc.; HC Wainwright & Co.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.